nodus-logo.png
Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme
September 08, 2022 01:15 ET | Nodus Oncology
Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme Acquisition enables Nodus Oncology to continue building its portfolio of first and best-in-class molecules...
nodus-logo.png
Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets
September 06, 2022 02:00 ET | Nodus Oncology
Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response...